Biomaterials Firm Bolt Threads, Formerly A Unicorn, Plans SPAC Deal At A $250 Million Valuation
CEO Dan Widmaier talks exclusively with Forbes about going public and the ups and downs of running a synthetic biology firm.
Source: forbes.com
Stay updated with breaking news from B Silk. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CEO Dan Widmaier talks exclusively with Forbes about going public and the ups and downs of running a synthetic biology firm.